VRCA

Verrica Pharmaceuticals Inc

3.47

Oct 20 • 3:59 PM ET +0.03 (0.87%)

3.52

Aftermarket • 7:30 PM ET +0.05 (1.44%)

Healthcare Biotechnology USA Micro NASD

Peers: PTHS ARQT SLGL DERM ACRS EVMN INCY DRMA EOLS BHC

| Held by: VTI VXF IWC AVTM

Scroll to Statements

Index	-
Market Cap	59.61M
Enterprise Value	50.22M
Income	-31.18M
Sales	30.32M
Book/sh	0.25
Cash/sh	0.65
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	76
IPO	Jun 15, 2018

P/E	-
Forward P/E	-
PEG	-
P/S	1.97
P/B	13.84
P/C	5.32
P/FCF	-
EV/EBITDA	-
EV/Sales	1.66
Quick Ratio	1.21
Current Ratio	1.33
Debt/Eq	0.42
LT Debt/Eq	0.20
Option/Short	Yes / Yes

EPS (ttm)	-1.67
EPS next Y	-1.34
EPS next Q	-0.50
EPS this Y	-21.69%
EPS next Y	34.55%
EPS next 5Y	8.78%
EPS past 3/5Y	38.35% 37.12%
Sales past 3/5Y	57.93% -
EPS Y/Y TTM	79.84%
Sales Y/Y TTM	106.21%
EPS Q/Q	-2971.63%
Sales Q/Q	-53.85%
Earnings	Aug 06 AMC
EPS/Sales Surpr.	-60.00% 2.24%

Insider Own	49.00%
Insider Trans	0.50%
Inst Own	27.14%
Inst Trans	-0.75%
ROA	-83.02%
ROE	-240.35%
ROIC	-604.20%
Gross Margin	85.89%
Oper. Margin	-87.18%
Profit Margin	-102.84%
SMA20	-16.14%
SMA50	-25.13%
SMA200	-40.08%
Trades

Shs Outstand	17.18M
Shs Float	8.76M
Short Float	2.24%
Short Ratio	2.88
Short Interest	0.20M
52W High	9.82 -64.67%
52W Low	3.28 5.79%
Volatility	9.08% 8.27%
ATR (14)	0.34
RSI (14)	30.71
Beta	1.65
Rel Volume	1.15
Avg Volume	68.22K
Volume	77,184

Perf Week	-3.07%
Perf Month	-22.72%
Perf Quarter	-39.12%
Perf Half Y	-45.09%
Perf YTD	-58.24%
Perf Year	-22.54%
Perf 3Y	-90.17%
Perf 5Y	-97.33%
Perf 10Y	-
Recom	1.29
Target Price	13.83
Prev Close	3.44
Price	3.47
Change %	0.87%

Date	Action	Analyst	Rating Change	Price Target Change
Aug-27-26	Initiated	Lake Street	Buy	$9
May-26-26	Resumed	H.C. Wainwright	Buy	$12
Nov-06-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-05-24	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
Jul-25-23	Upgrade	Needham	Hold → Buy	$10
Mar-22-23	Initiated	Jefferies	Buy	$10
Feb-13-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$4 → $11
May-25-22	Downgrade	RBC Capital Mkts	Outperform → Sector Perform	$16 → $4
May-14-21	Initiated	RBC Capital Mkts	Outperform	$19
Dec-24-20	Reiterated	H.C. Wainwright	Buy	$18 → $21
Jul-15-20	Downgrade	BofA Securities	Buy → Neutral
Jun-30-20	Reiterated	H.C. Wainwright	Buy	$24 → $18
Jun-24-20	Initiated	Northland Capital	Outperform	$21
Mar-24-20	Initiated	Needham	Buy	$20
Feb-21-19	Initiated	H.C. Wainwright	Buy	$20

Show Previous Ratings

Sep-30-26 08:00AM	Verrica Pharmaceuticals to Present New YCANTH Data Analysis at Two Upcoming Dermatology Conferences (GlobeNewswire) +7.51%
Sep-10-26 08:05AM	Verrica Pharmaceuticals to Present YCANTH and VP-315 Data at Two Upcoming Dermatology Conferences (GlobeNewswire)
Sep-08-26 08:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
Aug-28-26 06:47AM	Verrica completes enrolment in Phase III trial of Ycanth (Hospital Management) +12.23%
Aug-27-26 08:00AM	Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH for the Treatment of Common Warts, with Topline Data Expected Q1 2027 (GlobeNewswire)
04:05PM	Loading…
Aug-06-26 04:05PM	Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results (GlobeNewswire) -5.22%
04:01PM	Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital (GlobeNewswire)
Jul-30-26 08:00AM	Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026 (GlobeNewswire)
Jul-21-26 08:00AM	Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH for the Treatment of Molluscum Contagiosum in Israel (GlobeNewswire)
Jun-22-26 08:05AM	Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts (GlobeNewswire)
May-28-26 08:05AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-26 08:30AM	Verrica Pharmaceuticals Inc. Q1 2026 Earnings Call Summary (Moby)
08:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ (GlobeNewswire)
01:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2026 Earnings Call Highlights: Strong Revenue Growth and ... (GuruFocus.com)
May-12-26 04:01PM	Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results (GlobeNewswire)
08:35AM	Loading…
May-06-26 08:35AM	NanoViricides Measles Treatment Granted Orphan Drug Designation by FDA (Exec Edge) +17.74%
May-05-26 04:05PM	Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting (GlobeNewswire) +12.58%
08:00AM	Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026 (GlobeNewswire)
Apr-09-26 04:05PM	Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting (GlobeNewswire) -12.35%
Apr-06-26 08:00AM	Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference (GlobeNewswire) +9.32%
Mar-11-26 03:01PM	Verrica Pharmaceuticals Inc (VRCA) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
08:00AM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results (GlobeNewswire)
Mar-05-26 08:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026 (GlobeNewswire)
Feb-23-26 08:00AM	Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference (GlobeNewswire)
Feb-12-26 08:00AM	Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer (GlobeNewswire)
Feb-09-26 08:00AM	Verrica Pharmaceuticals Announces Launch of YCANTH for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical (GlobeNewswire)
Feb-02-26 12:00PM	Verrica Pharmaceuticals (VRCA) Upgraded to Strong Buy: Here's Why (Zacks) +5.97%
05:59AM	New Strong Buy Stocks for February 2nd (Zacks)
Jan-12-26 09:55AM	How Much Upside is Left in Verrica Pharmaceuticals (VRCA)? Wall Street Analysts Think 97.11% (Zacks)
Jan-07-26 08:00AM	Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH (VP-102) for the Treatment of Common Warts (GlobeNewswire)
08:00AM	Loading…
Nov-24-25 08:00AM	Verrica Pharmaceuticals Announces Private Placement Financing of $50 Million to Retire Debt and Extend Cash Runway (GlobeNewswire) +12.11%
Nov-17-25 04:00PM	Verrica Pharmaceuticals Inc (VRCA) Q3 2025 Earnings Call Highlights: Revenue Surge and ... (GuruFocus.com) -5.09%
Nov-14-25 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2025 Financial Results (GlobeNewswire)
Nov-10-25 08:00AM	Verrica Pharmaceuticals Presents New Data on VP-315 from its Phase 2 Clinical Trial in Basal Cell Carcinoma at the 40th Society for Immunotherapy of Cancer Annual Meeting (GlobeNewswire) +11.85%
Oct-24-25 11:00AM	Halper Sadeh LLC Encourages Verrica Pharmaceuticals, Inc. Shareholders to Contact the Firm to Discuss Their Rights (Business Wire)
Oct-20-25 04:05PM	Verrica Pharmaceuticals Receives Positive Feedback from the European Medicines Agency (EMA) Supporting a Clear Regulatory Path Forward to File for Approval of YCANTH in the European Union (GlobeNewswire) +7.95% -9.82%
Oct-07-25 04:05PM	Verrica Pharmaceuticals to Present New Data on VP-315 from its Phase 2 Trial in Basal Cell Carcinoma (BCC) at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting (GlobeNewswire)
Sep-19-25 08:00AM	Verrica Pharmaceuticals Announces That Development Partner, Torii Pharmaceutical, Receives Approval for YCANTH (TO-208) in Japan for the Treatment of Molluscum Contagiosum (GlobeNewswire) +8.66%
Sep-02-25 07:00AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference (GlobeNewswire)
Aug-13-25 03:12AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025 Earnings Call Highlights: Record Revenue Growth and ... (GuruFocus.com)
Aug-12-25 05:20PM	Verrica Pharmaceuticals Inc. (VRCA) Q2 Earnings and Revenues Beat Estimates (Zacks)
04:01PM	Verrica Pharmaceuticals Reports Second Quarter 2025 Financial Results (GlobeNewswire)
Aug-11-25 09:42AM	Verrica Pharmaceuticals Inc (VRCA) Q2 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com) +5.51%
Aug-06-25 05:10PM	Soleno Therapeutics, Inc. (SLNO) Reports Q2 Loss, Tops Revenue Estimates (Zacks) +9.20%
07:00AM	Verrica Pharmaceuticals to Report Second Quarter 2025 Financial Results and Provide a Corporate Update on August 12, 2025 (GlobeNewswire)
Jul-09-25 07:00AM	Verrica Pharmaceuticals Reports Strong Growth in YCANTH Dispensed Applicator Units in 2Q 2025 (GlobeNewswire)
Jul-01-25 07:00AM	Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire) +13.37%
May-28-25 08:00AM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire) -5.78%
May-14-25 08:10AM	Q1 2025 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
03:16AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2025 Earnings Call Highlights: Strong YCANTH Demand and ... (GuruFocus.com)
May-13-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q1 Loss, Tops Revenue Estimates (Zacks) +8.63%
04:05PM	Verrica Pharmaceuticals Reports Quarterly 2025 Financial Results (GlobeNewswire)
May-12-25 05:15PM	Assertio (ASRT) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +15.07%
09:52AM	Earnings To Watch: Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2025 Result (GuruFocus.com)
May-08-25 05:50PM	4D Molecular Therapeutics, Inc. (FDMT) Reports Q1 Loss, Lags Revenue Estimates (Zacks) +5.97%
May-07-25 08:00AM	Verrica Pharmaceuticals to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 13, 2025 (GlobeNewswire) -9.20%
May-02-25 07:10AM	Amneal Pharmaceuticals (AMRX) Q1 Earnings Beat Estimates (Zacks)
Apr-30-25 08:00AM	Verrica Pharmaceuticals to Participate in the Citizens Life Sciences Conference in New York (GlobeNewswire)
Apr-07-25 08:00AM	Verrica Pharmaceuticals Reports Strong Demand-Led Growth in YCANTH Dispensed Applicator Units in First Quarter 2025 (GlobeNewswire) +21.75%
Apr-02-25 04:05PM	Verrica Pharmaceuticals Appoints Gavin Corcoran, M.D. to its Board of Directors (GlobeNewswire)
Apr-01-25 09:55AM	Here's Why Verrica Pharmaceuticals (VRCA) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Mar-31-25 08:00AM	Verrica Pharmaceuticals to Participate in the 24th Annual Needham Virtual Healthcare Conference (GlobeNewswire)
Mar-26-25 07:00AM	Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer (GlobeNewswire) -6.75%
Mar-12-25 01:48PM	Q4 2024 Verrica Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents) -7.56%
03:08AM	Verrica Pharmaceuticals Inc (VRCA) Q4 2024 Earnings Call Highlights: Revenue Growth and ... (GuruFocus.com)
Mar-11-25 05:25PM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire)
Mar-03-25 07:00AM	Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 11, 2025 (GlobeNewswire)
Feb-27-25 10:00AM	Verrica Pharmaceuticals Inc. (VRCA) Expected to Beat Earnings Estimates: Should You Buy? (Zacks) -16.89%
Feb-25-25 04:05PM	Verrica Pharmaceuticals to Participate in the TD Cowen 45th Annual Health Care Conference in Boston (GlobeNewswire)
Jan-21-25 07:00AM	Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference (GlobeNewswire) +5.12%
Dec-20-24 07:00AM	Verrica Provides Business and Operational Update (GlobeNewswire)
Dec-09-24 04:15PM	Verrica Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -5.94% -7.84%
Dec-06-24 08:00AM	Verrica Pharmaceuticals Announces that Development Partner Torii Pharmaceutical Files New Drug Application of TO-208 the Treatment of Molluscum Contagiosum in Japan (GlobeNewswire)
Nov-21-24 07:30AM	Verrica Announces Pricing of $42.0 Million Public Offering (GlobeNewswire) +11.56%
Nov-20-24 04:05PM	Verrica Announces Proposed Public Offering (GlobeNewswire)
Nov-04-24 04:05PM	Verrica Pharmaceuticals Reports Third Quarter 2024 Financial Results and Announces Leadership Transition (GlobeNewswire) -6.54% -44.23%
Oct-24-24 07:00AM	Verrica Pharmaceuticals Announces Acceptance of Two Abstracts Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2024 Fall Clinical Dermatology Conference (GlobeNewswire)
Oct-09-24 06:21PM	Verrica Pharmaceuticals Inc (VRCA) Q2 2024 Earnings Call Highlights: Revenue Growth Amid Rising ... (GuruFocus.com)
Oct-02-24 07:30AM	Verrica Pharmaceuticals Announces Restructuring of Commercial Organization (GlobeNewswire) -18.98%
Sep-29-24 08:02AM	Verrica Pharmaceuticals Inc. (VRCA): Worst 52-Week Low Stock to Buy Now (Insider Monkey)
Sep-25-24 11:27AM	Is Verrica Pharmaceuticals Inc. (VRCA) The Worst 52-Week Low Stocks to Buy Now According to Short Sellers? (Insider Monkey) -5.68%
Sep-20-24 05:21AM	Notice to Long-Term Shareholders of Verrica Pharmaceuticals, Inc. (VRCA) (Newsfile) -6.70%
Sep-04-24 07:30AM	Verrica Pharmaceuticals to Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York (GlobeNewswire) +5.50%
Aug-15-24 07:32AM	Verrica stock drops after half patients tumours gone in skin cancer trial (Clinical Trials Arena) -6.73%
Aug-14-24 09:52AM	Why Is Dermatology-Focused Verrica Pharmaceuticals Stock Trading Lower On Wednesday? (Benzinga) -40.80%
08:55AM	Verrica Pharmaceuticals Inc. (VRCA) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
07:45AM	Verrica Pharmaceuticals Reports Second Quarter 2024 Financial Results (GlobeNewswire)
07:30AM	Verrica Pharmaceuticals Announces Positive Preliminary Topline Results from Part 2 of Phase 2 Clinical Study of VP-315, an Investigational Oncolytic Peptide-Based Immunotherapy for the Treatment of Patients with Basal Cell Carcinoma (GlobeNewswire)
Aug-06-24 07:30AM	Verrica Pharmaceuticals to Report Second Quarter Financial Results and Release Preliminary Topline Results from Part 2 of Phase 2 Trial of VP-315 for the Treatment of Basal Cell Carcinoma on August 14, 2024 (GlobeNewswire) -5.45%
Jul-15-24 11:57AM	7 Short-Squeeze Stocks That Could Beat Down the Bears (InvestorPlace)
Jul-01-24 07:30AM	Verrica Pharmaceuticals Announces Litigation Settlement with Dormer Laboratories, Inc. (GlobeNewswire) +9.05%
May-30-24 04:30PM	Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in New York (GlobeNewswire)
May-15-24 09:11AM	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth (MT Newswires)
07:30AM	Verrica Pharmaceuticals Announces Amendment to Company's Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study YCANTH for the Treatment of Common Warts (GlobeNewswire)
May-14-24 09:28AM	HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating (MT Newswires)
08:50AM	Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating (MT Newswires)
03:01AM	Verrica Pharmaceuticals Inc (VRCA) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-13-24 11:53AM	VRCA Stock Earnings: Verrica Pharmaceuticals Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace) +19.50%
09:12AM	Verrica Pharmaceuticals Inc (VRCA) Reports Q1 2024 Results: A Detailed Financial Review (GuruFocus.com)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Zawitz David	Chief Operating Officer	Aug 17 '26	Buy	4.98	6,000	29,880	27,000	Aug 18 05:00 PM
Rieger Jayson	CEO and President	Aug 14 '26	Buy	5.06	20,000	101,200	202,593	Aug 18 05:00 PM
Rieger Jayson	CEO and President	Aug 17 '26	Buy	4.91	5,000	24,550	207,593	Aug 18 05:00 PM
Rosenberg Noah L.	CMO	Aug 17 '26	Buy	4.91	4,200	20,622	6,557	Aug 18 05:00 PM
Rosenberg Noah L.	CMO	Aug 18 '26	Buy	4.92	2,030	9,988	8,587	Aug 18 05:00 PM
Kirby John J.	Interim CFO	Aug 18 '26	Buy	4.93	5,000	24,650	23,962	Aug 18 05:00 PM
Rosenberg Noah L.	CMO	Nov 25 '25	Buy	4.24	2,357	10,000	2,357	Nov 25 07:00 PM
Kirby John J.	Interim CFO	Nov 25 '25	Buy	4.24	3,536	15,001	8,962	Nov 25 07:00 PM
Zawitz David	Chief Operating Officer	Nov 25 '25	Buy	4.24	10,000	42,425	21,000	Nov 25 07:00 PM
Rieger Jayson	CEO and President	Nov 25 '25	Buy	4.24	94,311	400,114	182,593	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	2,750,762	11,670,108	3,348,372	Nov 25 07:00 PM
Manning Paul B	Director	Nov 25 '25	Buy	4.24	1,375,380	5,835,050	3,958,189	Nov 25 07:00 PM

Verrica Pharmaceuticals, Inc. is a dermatology therapeutics company, which engages in identifying, developing, and commercializing pharmaceutical products for the treatment of skin diseases. Its products include Pipeline VP-102, Pipeline VP-103, and Pipeline VP-315. The company was founded by Matthew Davidson on July 3, 2013 and is headquartered in West Chester, PA.

Ph.D.Dr. Jayson M. Rieger M.B.A.

Interim Chief Financial OfficerMr. John J. Kirby CPA

Chief Medical OfficerDr. Noah L. Rosenberg M.D.

COOMr. David Zawitz

Executive Vice President of Technical OperationsMr. Eugene Scavola

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

VRCA

Verrica Pharmaceuticals Inc

Upgrade your Finviz experience